Gain Therapeutics: A Biotech with Promising Treatments for Neurodegenerative Diseases and a Note from Prohost Biotech

Gain Therapeutics Inc in the News
Gain Therapeutics, Inc. (GANX) announced today topline data from its  study conducted at the University of Maryland School of Medicine (UMSOM). The study, evaluating two lead Structurally Targeted Allosteric Regulators (STARs) compounds – GT-02287 and GT-02329 – for the treatment of Gaucher and GBA1 Parkinson’s Disease, demonstrated positive effects . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.